Sunitinib and other targeted therapies for renal cell carcinoma
| Autor: | M. Mantle, Paul Nathan, Robert Jones, A. Bex, Thomas E. Hutson, Louise Lim, Simon Chowdhury, Thomas Powles |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Vascular Endothelial Growth Factor A
Sorafenib Oncology Cancer Research medicine.medical_specialty Indoles Bevacizumab sunitinib medicine.medical_treatment renal cancer Targeted therapy Pharmacotherapy Renal cell carcinoma Internal medicine Biomarkers Tumor medicine Humans Pyrroles Molecular Targeted Therapy Neoplasm Metastasis Carcinoma Renal Cell Randomized Controlled Trials as Topic Sunitinib business.industry Cancer Prognosis medicine.disease VEGF Kidney Neoplasms Drug Resistance Neoplasm Immunology mTOR Drug Therapy Combination Minireview business Kidney cancer medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change. In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will describe the major areas of clinical research that will report over the next few years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|